drugset
drugset / Trial / NCT03311945

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

NCT03311945 ↗

Phase 3 Completed 33 enrolled Judit Pich Fundacion Clinic per a la Recerca Biomédica · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD): Roll-over study of the RALAM clinical trial (NCT02284035)

Timeline

Start
2018-05-02
Primary completion
2021-03-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 300 mg —
Subject Raltegravir Other / unclassified 1200 mg —

Indications

HIV infectious disease